Banner - NPPA Connect
|Articles|April 5, 2019

Revive joins Belotero product range in Europe

Merz announced the launch of Belotero Revive, Friday, April 5, in selected countries in Europe and Latin America. The new “beauty booster” is designed to improve hydration, elasticity and skin firmness with a combination of hyaluronic acid and glycerol. It is injected beneath the skin to reduce the appearance of fine lines, or as an early intervention treatment, to slow the progression of facial aging, the company says.

“Strong scientific research forms the basis for this new dermal injectable and our study results show that treatment with this beauty booster is an effective way to provide direct skin hydration and increase skin smoothness, giving our patients beautiful, natural-looking results,” said Prof. Dr. Martina Kerscher, Professor of Dermatology, University of Hamburg and lead author of the BELOVE study.

In a clinical study, 24 patients received injections in the lower cheek area of the face and were observed over a 36-week period. Patients saw a gradual reduction in redness over 36 weeks and noticed improved skin hydration after one week of treatment, which continued to improve up to week 36. All 24 patients noted improvement at 12 weeks and 80% were satisfied with treatment at week 24.

According to the company, Belotero Revive targets a new generation of aesthetic patients who are focused on addressing early signs of aging. The product will be launched within additional markets later this year.


Related to this article

Day 3 Recap: Fall Clinical 2026
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
Day 2 Recap: Fall Clinical 2026
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.